HANSOH PHARMA News

[Brokerage Focus] HTSC gives HANSOH PHARMA (03692) an initial "Buy" rating with a Target Price of 22.28 HKD.

Jinwu Financial NewsDec 30, 2024 15:35

Hanson Pharmaceuticals (03692.HK): US$0.112 billion down payment granted to MSD for preclinical oral GLP-1

Huayuan SecuritiesDec 30, 2024 07:27

Hanson Pharmaceuticals (3692.HK): Innovative, Honorable, and Welcoming Chuxin

HTSCDec 29, 2024 00:00

Hanson Pharmaceuticals (03692.HK): Oral GLP-1 Authorizes MSD BD Strategy Next

China International Capital CorporationDec 26, 2024 07:37

Bank of America Securities: Reiterates Buy rating for INNOVENT BIO (01801) and HANSOH PHARMA (03692) with both Target Prices raised.

Zhitong FinanceDec 20, 2024 11:52

HANSOH PHARMA (3692.HK): ORAL GLP-1 CANDIDATE TRANSACTION WITH MSD

Zhao Silver InternationalDec 20, 2024 08:37

Morgan Stanley: Maintains "Shareholding" rating on HANSOH PHARMA (03692) with a Target Price of 24 Hong Kong dollars.

Zhitong FinanceDec 19, 2024 11:29

Goldman Sachs: Initiates coverage on HANSOH PHARMA (03692) with a "Buy" rating and a Target Price of HKD 20.97.

Zhitong FinanceDec 19, 2024 09:55

[Brokerage Focus] Bocom Intl raises hansoh pharma (03692) target price by 17.6% and upgrades rating to buy.

Jinwu Financial NewsDec 3, 2024 09:25

Hanson Pharmaceuticals (3692.HK): Amelot's sales growth momentum is sufficient, and the value of the R&D pipeline is about to be realized and raised to purchase

bocom intlDec 2, 2024 00:00

[Brokerage Focus] Minsheng Securities gives hansoh pharma (03692) an initial "Recommended" rating, bullish on the company's continued efforts in the oncology field.

Golden Watch Financial NewsNov 27, 2024 09:25

Hanson Pharmaceuticals (3692.HK) First Coverage Report: Self-developed+BD two-wheel drive innovation transformation has borne fruit

Minsheng SecuritiesNov 26, 2024 18:57

Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.

Zhitong FinanceOct 17, 2024 09:53

Huachuang Securities: Maintaining a "recommended" rating for Hansoh Pharma (03692) with a target price of 25.44 Hong Kong dollars.

Zhitong FinanceSep 30, 2024 09:39

Hanson Pharmaceuticals (03692.HK) 2024 Interim Report Review: The sharp increase in revenue from innovative drugs accounts for a new high proportion of revenue

Huachuang SecuritiesSep 30, 2024 07:36

HANSOH PHARMA(3692.HK):STRONG SALES GROWTH OF INNOVATIVE DRUGS

Aug 29, 2024 19:59

Hanson Pharmaceuticals (03692.HK): Innovation drives high performance, overseas BD is gradually realized

德邦證券Aug 29, 2024 19:06

CICC: Maintains the 'outperform industry' rating on Hansoh Pharma (03692) with a target price raised to 21.12 Hong Kong dollars.

Zhitong FinanceAug 29, 2024 09:51

Hanson Pharmaceuticals (03692.HK): Overseas licensing boosts performance, and the share of innovative drug revenue continues to rise

Aug 29, 2024 09:42

Hansoh Pharmaceutical Group Company Limited(03692.Hk):Continuous Sales Ramp up of Innovative Products

Juyuan Research ReportAug 28, 2024 19:56